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The study of binding kinetics of proteins plays an important role in understanding
molecular mechanisms that drive biological processes. The binding rate constants reflect
the dynamics of the system and associated biological activity measurements of the
association and dissociation rate constants make it possible to compare different
interactions in a standardized manner and help elucidate a mechanistic understanding of
binding events.
In our study, we used Surface Plasmon Resonance (SPR) technology (Biacore) to
study the binding kinetics of the antibodies EGF, Cetuximab and a candidate drug P-13
with the receptor EGFR. The candidate drug P-13 was synthesized and tested on Biacore
for binding kinetics. This peptide is anticipated to bind to domain III of EGFR-ED. The
study also compared the interaction kinetics of EGF/EGFR and Cetuximab/EGFR with the
previous literature and a summary of results is produced.
Our Biacore experiments on EGF/sEGFR suggest a two-state affinity binding with
90% high affinity binding sites, which compares with the previous studies in cells. The
dissociation rate constant for Cetuximab/sEGFR interaction was reported for the first time
using SPR while the other kinetic constants were comparable to literature. Although the
peptide P-13 demonstrated a relatively weak (micro molar) binding capacity to the
receptor, as compared with EGF and Cetuximab, the dissociation rate constant was
comparable to a nano molar binder. Hence, we argue that the region of binding of P-13 is
sterically inhibited as per the receptor orientation, which is consistent with the computer
design data supplied with this candidate drug.

xii

CHAPTER 1 Introduction

1.1 Overview

Cancer is one of the major causes of death in the U.S. It starts as the cell begins to
divide uncontrollably. This cell multiplication eventually leads to a visible mass called a
tumor. Tumor start as benign, which are not fatal, but sometimes change into malignant
tumors as characterized by spreading (metastasis) to multiple regions of the body. The type
of the cancer is identified by the initial tumor location. There are more than 100 types of
cancer, including breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and
lymphoma (Jemal et al., 2008).
Colorectal cancer is the third most common cancer found in U.S. The American
Cancer Society estimates that there will be about 108,700 new cases of colon cancer and
40,740 new cases of rectal cancer in 2008. Combined, this might cause 49,960 deaths in
U.S alone. Colorectal cancer, cancer that starts either in the colon or the rectum, is treated
by surgery, radiation therapy, chemotherapy or targeted therapies called monoclonal
antibodies.
Although surgery, radiation therapy, and chemotherapy are suggested treatments for
cancer, there are common side effects including bleeding from surgery, damage to nearby
13

organs during operation, mild skin irritation due to radiations, nausea, diarrhea, rectal and
bladder irritation, tiredness. While chemotherapy kills cancer cells, it also damages some
normal cells which cause side effects like increased chance of infection, hair loss, easy
bleeding or bruising after minor cuts or injuries.
Targeted therapies (monoclonal antibodies) are used to destroy some types of cancer
cells while causing little harm to normal cells. They are designed to recognize certain
proteins (receptors) that are found on the surface of particular cancer cells. The major
criteria for the proteins to be targets for treatment are that they should be accessible to the
antibodies and be available during the whole treatment time. In this thesis, we concentrate
on EGFR (Epidermal Growth Factor Receptor), the target receptor, whose constitutive
activity leads to cell proliferation and, in turn, cancer. EGFR is highly upregulated in
colorectal cancers and, thus, has received significant attention as a target for drug
development.

1.2 Objective

In this thesis, the binding kinetics of the drug Cetuximab (monoclonal antibody) and
the growth factor EGF (Epidermal Growth Factor) with sEGFR (soluble EGFR) were
studied using SPR (Surface Plasmon Resonance). The kinetic rate constants and the
methods used to obtain values for EGF and Cetuximab (C225) interactions with sEGFR
are compared to that in the literature. Our goal is to carry on SPR studies in an

14

arrangement which would imitate the natural system as closely as possible in order to
obtain kinetic constants consistent with cellular-based results.

A thirteen residue peptide, code named P-13, has been proposed as an EGFR inhibitor
that binds to residues near 500 of domain III (Peters, 2009). One of the goals of this
research is to test P-13 in Biacore and compare its binding to that of EGF and Cetuximab.

15

CHAPTER 2 Theory

2.1 EGF Pathway: Cell growth and proliferation

The epidermal growth factor receptor (EGFR) family, also called ErbB family,
consists of four kinds of receptors, EGFR (ErbB1), Neu (ErbB2), ErbB3, and ErbB4. Each
receptor consists of a cytoplasmic tyrosine kinase domain, a single transmembrane
spanning region, and an extracellular region, the latter of which contains approximately
620 amino acids. The extracellular region of each receptor has four domains, L1 and L2 (or
I and III), which are luecine-rich regions and CR1 and CR2 (or II and IV), which are
cystine-rich (Ferguson et al., 2003). The ligand EGF binds to the extracellular domain of
the receptor and aids in the dimerization of the receptors to activate the signal cascade for
gene transcription and cell proliferation.
The EGF receptor has many growth factors, such as Epidermal Growth Factor (EGF)
and Transforming Growth Factor-α (TGF-α). EGF when bound to the extracellular domain
of EGFR leads to receptor dimerization and activation of tyrosine kinase enzyme located in
the intracellular domain of the receptor. Kinase activation leads to transphosphorylation of
the receptor intracellular domains and initiates multiple signal transduction pathways that
eventually result in the signal reaching the nucleus.
16

Figure 2.1-1 EGF receptor signal transduction pathway

The Ras-Raf-MEK-MAPK pathway is activated through the growth factor receptor
bound protein 2 (GRB2)-SOS complex. The receptor mediated signaling also activates
phosphotidylinositol 3-kinase (PI3K)-AKT pathway, which contributes to anti-apoptic
effects of EGFR activation. Additionally, transcription activator (Stat) proteins are also
activated. These EGFR downstream signaling pathways lead in cellular responses like cell
proliferation, differentiation, cell motility, adhesion and angiogenesis. The over
expression, mutation or truncation of the EGF receptor leads to constant activity of the
receptor and hence leads to excess cell growth and, in turn, cancer. EGFR is implicated in
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the development of wide range of epithelial cancers, including those of breast, colon, head
and neck, kidney, lung, pancreas and prostate (Scaltriti et al., 2006).

2.2 Cancer Research: Antibodies

Recent research has explored promising methods to suppress tumor growth in tissues.
Over the last decade, targeted therapies have been proven to be an effective way to inhibit
tumors with fewer severe adverse events in cancer intervention since they specifically
interfere with signaling pathways essential for tumor growth. Monoclonal antibodies and
protein tyrosine kinase inhibitors are two classes among these new therapeutic
interventions.
The monoclonal antibodies target the extracellular ligand binding domain of the
receptor and prevent the activation of the receptor by its respective growth factor. On the
other hand, tyrosine kinase inhibitors are small molecules which mainly target the ATP
binding domains of the receptor and thereby prevent phosphorylation of the kinase domain
and its activation.
One simple and effective way to treat tumors is the use of monoclonal antibodies
along with other cancer therapies or individually. Monoclonal antibodies are produced by
forming a hybrid cell that has the ability to produce the desired antibody continuously. In
this technology, the tumor cells that can replicate endlessly are fused with mammalian
cells that produce the antibody. This results in “hybridoma”, the fused cell, which

18

continually produces the antibody. The antibodies thus produced are pure as they come
from only one type of cell (Schwaber, J et al., 1973).
Monoclonal antibodies function in cancer treatment through various mechanisms.
They can directly affect the tumor by causing apoptosis or programmed cell death. They
can compete with growth factors in binding to receptor domains and thereby arrest
signaling for cell proliferation. These antibodies can be also used in the clinic as
conjugated antibodies, with a radionuclide or chemotherapy agent attached or as nonconjugated antibodies, without any toxins or radionuclide attached to them.
The FDA (Food and Drug Administration) approved the first monoclonal antibody for
cancer treatment in 1997. Today several of these drugs are in market for treating certain
cancers. Below is the table of the MAbs approved by the FDA for cancer treatment.

Table 2.2-1 Monoclonal antibodies used to treat cancer (Rang, H.P. et al., 2003)

MAb Name
Rituximab
Trastuzumab
Gemtuzumab ozogamicin

Trade
Name
Rituxan
Herceptin
Mylotarg

Alemtuzumab

Campath

Ibritumomab tiuxetan
Tositumomab
Cetuximab

Zevalin
Bexxar
Erbitux

Bevacizumab

Avastin

Panitumumab

Vectibix

Used to Treat

Approved
in:
Non-Hodgkin lymphoma
1997
Breast Cancer
1998
Acute myelogenous leukemia 2000
(AML)
Chronic lymphocytic leukemia 2001
(CLL)
Non-Hodgkin lymphoma
2002
Non-Hodgkin lymphoma
2003
Colorectal cancer
2004
Head & neck cancers
2006
Colorectal cancer
2004
Non-small cell lung cancer
2006
Advanced breast cancer
2008
Colorectal cancer
2006
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Cetuximab (Erbitux) is an antibody against EGFR protein as it blocks the activation
of this receptor. It was approved by FDA in 2004 for treatment of colorectal cancer.
Recently, it was approved for the treatment of head and neck cancers (2006).

2.3 Binding studies: EGF/Cetuximab/P-13 with EGF Receptor

Structural studies on EGF-EGFR complex have shown that the growth factor binds to
the domains I and III of extracellular-EGFR simultaneously. The unliganded EGF receptor
is in its unextended form (inactive state) with domain II buried by an intramolecular
interaction with domain IV. When the growth factor binds to the receptor (domains I and
III), it alters the spatial arrangement of the domains and this domain rearrangement
exposes a critical region, known as the dimerization arm, of domain II. This aids in the
dimerization of the receptor and thus activation of cell signaling (Li et al., 2005).

Figure 2.3-1 Model for EGF induced activation of EGFR

20

Cetuximab, as shown in structural studies, binds exclusively to domain III of the EGF
receptor that overlaps the EGF binding site. Thus, it prevents the EGF from binding to the
receptor and thereby prevent tumor causing cell signaling (Li et al., 2005).

C Ligand

E
C

C

A. Tethered monomers

B. Cetuximab bound
to domain -III

E

C. EGF cannot
induce dimerization .

Figure 2.3-2 Model for Cetuximab preventing EGF binding to EGFR

P-13 is a thirteen residue peptide which is anticipated to bind domain III of EGFR
extracellular region. The peptide binds to residues near 500 of domain III (Peters, 2009)
and Figure 2.3-3 shows the binding regions of peptide on sEGFR.

Figure 2.3-3 Structure of P-13 binding to EGFR-ED
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CHAPTER 3 Literature Review

3.1 Overview of the Chapter

In this chapter, we review previously published studies on the binding of antibodies
EGF and Cetuximab to EGFR. We compare studies carried over in cells with that on
Biacore. In the later part of this chapter, important Biacore phenomena are discussed.

3.2 Review of Previous Studies on Binding of EGF to Heterogeneous EGFR

Epidermal growth factor (EGF) is known to bind to its receptor (EGFR) with an
equilibrium dissociation constant (KD) of 1-10nM in living cells. Quantitative binding
experiments demonstrated that EGF binds to EGFR with two distinct dissociation
constants: a minority (2%–5%) of high-affinity (KD~0.1nM) receptors and a majority
(95%–98%) of low-affinity (KD~10nM) receptors. The two site binding leads to concaveup type Scatchard plots (Schlessinger et al., 1986, 88). The structural identifications of
different conformations of the EGFR extracellular regions suggested that the low affinity
binding sites might represent receptors in the auto-inhibited conformation, whereas high
affinity binding sites might be accounted for by receptors in the active, extended
22

configuration (Klein et al, 2003(6-11)). However, this hypothesis could not explain the
concave-up character of the experimentally observed Scatchard plots. Furthermore, the
data does not support the dimerization model, which assumes that receptors in the active
conformation bind ligand with high affinity and form receptor-receptor dimers (Klein et
al., 2003). Ozcan et al., argued that the concave-up curvature typical of an EGF binding
Scatchard plot for wild type EGFR can be simulated only by including in the model a
saturable high affinity external site for receptor dimers. Additionally, they argued that the
so called low affinity EGF-binding sites seen in studies of the wild-type EGFR represent
the interconverting tethered and extended (dimerizing) form of the receptor extracellular
domain inferred from structural studies (Ozcan et al., 2006). Further studies by Macdonald
et al., proposed that the concave-up Scatchard plots can be explained by including negative
cooperativity in the system. The results from Macdonald et al., studies indicated that the
affinity of EGF binding to the second site on a dimer (2.9nM) is 15-fold less than the
affinity of EGF for binding the first site on a dimer (190pM). All of these studies supported
that intracellular domain is required to account for concave-up Scatchard plots although it
is clear that the extended configuration of the EGFR binds EGF with higher affinity than
does the unextended configuration (Klein et al., 2003). All the above mentioned studies
were carried in cells.
In non-cellular studies using soluble extracellular EGFR, the binding experiments and
structural data suggest that EGF can bind to the sEGFR in at least two separate types of
binding events (Lemmon et al., 1997). However, the generated Scatchard plots were not of
concave-up character (Klein et al., 2003). In previous Biacore studies using soluble
23

extracellular EGFR, the apparent KD for EGF binding was reported to be 100-400nM
(Wade et al., 2002, Iyer et al., 2007, Ferguson et al., 2003). Wade et al., reported that
analysis of equilibrium binding data in Scatchard format for Biacore studies of
EGF/sEGFR interaction gave an excellent linear fit (R=0.992) and indicated a KD of
292nM but the curves did not fit ideally to a 1:1 Langmuirian model. A better fit was
obtained with a model that comprised a small percentage of high affinity component
indicating two independent binding events. The presence of high affinity was also
suggested from Biacore solution competition data and fluorescence anisotropy experiments
yielding biphasic Scatchard plots (Domagala et al., 2000).
Based on the previous Biacore studies, we designed our experiment for EGF/sEGFR
interaction such that it closely imitates the physiologically active system of cell. We aimed
to reproduce the literature binding kinetics and tried to explore further into the concepts of
multiple binding events. A summary of the previous studies is given in Table 2.

Table 3.2-1 Experimental systems used for EGF/EGFR interaction

Reference
Schlessinger
et al., 1986,
88.
Domagala et
al., 2002
Wade et al.,
2000

Analyte

Ligand

Type of
Study

EGF

EGFR

In cells

Heterogeneous

Results
(Scatchard
Plot)
Curvilinear

hEGF

sEGFR

Biacore

Heterogeneous

Biphasic

sEGFR

mEGF

Biacore

Heterogeneous

Linear

24

Interaction
type

3.3 Review of previous studies on Cetuximab binding to EGFR

Cetuximab is a chimeric monoclonal antibody of the immunoglobulin G1 (IgG1) class
that is directed against the human epidermal growth factor receptor (EGFR) and binds to
extracellular domain of the receptor with high specificity. Cetuximab has been developed
jointly by Merck, KGaA, and ImClone Systems Incorporated/Bristol-Myers Squibb for the
treatment of several types of human cancer that express EGFR, including colorectal cancer,
squamous cell carcinoma of the head and neck, nasopharyngeal cancer, pancreatic cancer,
ovarian cancer, and non-small cell lung cancer.
Biacore binding studies of Cetuximab Fab fragment with sEGFR have shown a
simple 1:1 Langmuir binding with an apparent KD of 2.3±0.5nM (Li et al., 2005). In this
experiment, Cetuximab Fab fragment was immobilized and sEGFR was made to flow on
the surface. In the studies carried over by Tikhomirov et al, sEGFR was immobilized on
the sensor surface and Cetuximab was used as analyte. These studies reported binding in
both high as well as low sEGFR surface density scenario. Low immobilization levels of
sEGFR were used to represent monovalent binding conditions and high immobilization
levels were used to show bivalent binding conditions. In studies carried over by Goldstein
et al., an equilibrium dissociation constant of 0.2nM was reported using Biacore studies
where sEGFR was amine coupled to the surface and Cetuximab was the analyte.
In our studies, we tried to imitate the system close to that in living cells, immobilizing
sEGFR to the surface. Also, we used two different surface densities (one higher and the
other lower) to compare the binding of Cetuximab to explain avidity effects on the surface.
25

We reported the kinetic dissociation rate constant of Cetuximab/sEGFR interaction for the
first time in our studies.

3.4 Considerations for Biacore experiments

The following constraints must be considered while designing a binding experiment
on Biacore and analyzing the data obtained.

3.4.1 Mass Transport

Biacore has a flow cell which consists of a sensor surface on top of which one of the
interactants (ligand) is immobilized. The other interactant (analyte) is passed over the flow
cell and binding is determined by the optical system.
In Biacore, analyte is transported by diffusion and flow to the sensor surface, where it
reacts with the immobilized receptor (Myszka et al., 1998). Under laminar flow conditions
used in Biacore, the rate of transport of the analyte to the surface is proportional to the
cube root of the flow rate, and is also influenced by the dimensions of the flow cell and the
diffusion properties of the analyte (Jason-Moller et al., 2006). The interaction is reaction
limited when the transport of analyte to the surface is much faster than the rate of analyte
association with the ligand. The observed binding here will be determined by the kinetic
rate constants (Jason-Moller et al., 2006). On contrary, the binding is mass transport
limited when the rate of analyte transport to the surface is slower than the reaction rate of
26

analyte to the ligand. This may lead to partial or no kinetic information of the binding.
Optimal assay conditions have to be determined to minimize mass transport limitations to
get reliable kinetic information.
From the Biacore studies, it was determined that mass transport limitations majorly
depend on two factors: surface density of the ligand and flow rate of the analyte to the
surface. As the receptor density on the sensor surface is increased, the binding reaction at
the surface speeds up, and the binding kinetics become transport limited (Myszka et al.,
1998). High flow rates help in delivering consistent amount of sample to the surface.
Hence, the kinetics is best studied under conditions of high flow rates and low surface
binding capacity. In practice, this translates to using ligand densities that result in a
maximum analyte binding response no greater than 50 to 150RU and flow rates greater
than 30µl/min (Jason-Moller et al., 2006).

3.4.2 Analyte Concentrations

Analyte concentrations play an important role in accurately determining the
equilibrium or association rate constants correctly. The surface is said to be 50% saturated
with analyte at the concentration equal to equilibrium dissociation constant KD. It is
recommended that the concentrations cover a full range of “binding curves” showing
barely binding of analyte to “saturation binding”. Reliable detailed kinetic analysis
requires data from four to six analyte concentrations, spanning the range of 0.1 to 10 times
KD (Jason-Moller et al., 2006). Analytes should be in the same buffer as the continuous
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flow buffer to minimize bulk refractive index differences that can lead to low signal-tonoise ratios. This is often most easily achieved through dilution of a concentrated analyte
stock into running buffer. Kinetic assays should include a series of start-up cycles using
buffer as analyte to equilibrate the surface as well as cycles with zero concentration of
analytes as part of the concentration series for the purposes of reference subtraction
(Myszka et al., 1999). Although it is not necessary to reach equilibrium, it is recommended
that the association times used be sufficient for at least one analyte concentration to reach
steady state. To accurately determine dissociation rate constants, a measurable decrease in
signal should occur during the dissociation period (Jason-Moller et al., 2006).
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CHAPTER 4 Experimental Background

4.1 Surface Plasmon Resonanace

Surface Plasmon Resonance (SPR) is a relatively new technique used to measure
biomolecular interactions in real time. This is done in a label free environment, while one
of the interactants is immobilized on to the sensor surface and the other is passed over the
surface. The association and dissociation of the interactants are measured in resonance
units (RU) and plotted as a Sensogram.

4.1.1 Principle of SPR

SPR is a phenomenon that occurs in thin conducting films at an interface between
media of different refractive indices. In the Biacore instrument, the conducting film is thin
layer of gold, and the media are the glass of the sensor chip and the sample solution. When
a plane polarized light is incident onto the reflecting interface, under conditions of total
internal reflection, an electric field intensity known as an evanescent wave is generated.
This evanescent wave is exponentially detenuating with distance from the surface. At a
specific incident angle and energy (wavelength), the incident light excites plasmons in the
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gold film and SPR is seen as a drop in the intensity of the reflected light due to the
resonance energy transfer between evanescent wave and surface plasmons. The resonance
conditions are influenced by the material absorbed onto the thin metal film and the SPR
signal depends on the refractive index of solutions in contact with the surface.

Figure 4.1-1 Demonstration of Surface Plasmon Resonance. The binding of analyte shifts the SPR angle
from position I to II.

In Biacore, the immobilized molecule on the surface is called the ligand and the
molecule that flows over the surface is called the analyte. As analyte binds to the ligand,
there is accumulation of protein on the surface which results in an increase in the refractive
index. This change in refractive index is measured in real time and plotted as response or
resonance units (RU) versus time. This plot is called a Sensogram and gives information
on kinetics, affinity, binding specificity and concentration profiles. The technology allows
determination of these parameters with analytes ranging in size from about 150 to 106
g/mole (Dalton).
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Figure 4.1-2 Sensogram

4.2 Instrumentation

The Biacore instrument is composed of three main units: the optical system, a liquid
handling system and the biosensor chip. The instrument is connected to a PC running
Biacore, where the results are presented in real time as a Sensogram.
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Figure 4.2-1 Three corner stones of Biacore technology

4.2.1 Optical System

The optical system is responsible for generation and detection of the SPR signal. It
detects all surface changes in refractive index as the mass changes in the aqueous layer
close to the sensor chip surface. The optical unit has a glass prism on to which the glass
slide of the sensor chip is kept in contact. A good optical coupling between the prism and
sensor chip is ensured by a silicone opto-interface. Light is focused through the prism on to
the sensor chip surface from a near-infrared light-emitting diode (LED), giving a fixed
range of incident light angles. Light reflected from the sensor chip is monitored by a linear
array of light-sensitive diodes covering the range of incident light angles. By using a
wedge of incident light and a fixed array of detectors, the SPR angle is monitored
accurately in real time (Bia technology handbook).
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4.2.2 Liquid Handling System

The liquid handling system with precision pumps and an integrated microfluidic
cartridge (IFC) in Biacore maintains a constant flow of sample and buffer over the sensor
chip surface. The autosampler in the system helps in transferring, diluting and mixing
samples, injecting samples into the IFC. One of the two pumps maintains a continuous
flow of liquid through the detector flow cell while the other assists in the working of the
autosampler. Samples are transferred through a needle from the autosampler into the IFC,
which connects with the flow cells. The microfluidic system allows single or multichannel
analysis in up to four flow cells. One of the flow cells can be used as a true reference
during sample injection, allowing blank-subtracted data to be presented on screen during
analysis. The data obtained thus enhances the signal quality and maximizes the resolution.

4.2.3 Sensor Chip

The Biosensor chip is a glass slide coated with thin layer of gold, creating the
physical conditions required for generating an SPR signal. This forms the base for the
attachment of a range of specialized surfaces designed to optimize the binding of various
molecules (Malmqvist et al., 1999). On most sensor chips, a matrix of carboxymethylated
dextran layer is covalently attached to the gold surface forming a surface layer of
approximately 25-100nm thick. The dextran layer maintains a hydrophilic environment
suitable for a variety of protein interactions and helps in covalent immobilization of bio
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molecules. The sensor chip can be divided into four flow cells and each flow cell can be
used independently (Wei et al., 2004).
Sensor chip CM5 is the most commonly used versatile chip which supports
immobilization of wide range of ligands from small organic molecules to proteins, nucleic
acids and carbohydrates. Molecules are covalently coupled to the sensor surface via amine,
thiol, aldehyde or carboxyl groups. The chip is mounted on a plastic support frame that is
protected by a plastic cassette.
Some other sensor chips include sensor chip SA which is used to capture biotinylated
peptides, proteins and DNA, sensor chip NTA which is used to capture ligands via metal
chelation, sensor chip HPA which is for membrane biochemistry and the study of
membrane associated receptors.

4.3 Immobilization

Biomolecules for interaction can be attached to the sensor surface using two different
approaches: Covalent immobilization and Capturing methods.

4.3.1 Covalent Immobilization

Covalent immobilization is the most commonly used approach for attaching the
ligand to the dextran matrix on the sensor surface. The various covalent immobilization
chemistries used are: Amine coupling, which couples amine groups on the ligand to the
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carboxyl groups on the dextran matrix; Thiol coupling, which is used when there can be
thiol-disulfide exchange between thiol groups and active disulfides introduced on either the
ligand or the surface matrix; Aldehyde coupling, which is used when there can be reaction
between hydrazine or carbohydrazide groups introduced on the surface and aldehyde
groups obtained by oxidation of carbohydrates in the ligand.
Covalent immobilization may have limited stability under certain conditions, although
it generally results in stable attachment of ligand to the surface under the buffer conditions
normally used for interaction analysis and regeneration. Also, it might involve chemical
modification of the ligand which can potentially affect the analyte-binding activity. But
most ligands can be immobilized without losing activity by one or the other chemistry.

4.3.2 Capturing Approaches

Capturing is the best alternative approach when covalent immobilization results in
loss of ligand activity or is unsuitable for other reasons. The capturing molecule is
covalently attached to the matrix to which the ligand is immobilized. The ligand
interaction with the capturing molecule should have a high affinity so that the ligand does
not detach from the molecule during analysis. Capturing approach does not introduce
conformational changes in the ligand and the orientation of ligand is in a specific direction.
But capturing approaches consume more ligand when fresh material has to be captured for
each analysis since some ligand dissociates from the surface during regeneration. The
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common capturing approaches are streptavidin- or avidin-biotin capture, antibody-based
capture, and capture of tagged proteins.

4.4 Amine Coupling

Amine coupling is used to immobilize molecules which contain amine groups. This is
the most generally used coupling chemistry since most of the biomolecules contain amine
groups. Firstly, carboxyl groups on dextran surface are activated by passing a mixture of
EDC and NHS to yield reactive ester groups. Ligand is then passed over the surface where
the esters spontaneously react with primary amine groups or other nucleophilic groups on
the ligand and link it covalently to the dextran matrix. Injection of ethanolamine after
ligand immobilization deactivates the remaining active ester groups on the surface and
removes non-covalently bound ligand. Typical Sensogram of amine coupling is shown in
Figure 4.4-1.

36

Figure 4.4-1 Illustrative graph of Amine coupling

4.5 Kinetics

Biacore has several applications which include defining the characteristics of proteins
in terms of their specificity of interaction with other molecules, their affinity of binding to
other molecules, and the rates at which they interact (Karlsson et al., 2006). Biacore
system also provides accurate concentration measurements.
The application of interest in this project is kinetics since it provides dynamic binding
information as in actual cellular processes. As the analyte binds to the ligand, there is
increase in mass at the sensor surface which is recorded as association phase and as analyte
dissociates from the ligand, the decrease in mass at the surface is recorded as dissociation
phase in the Sensogram. When the rate of association and rate of dissociation are equal,
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there is equilibrium established, which is marked by steady state in the Sensogram. For 1:1
Langmuir interaction, the dissociation constant, KD, is the ratio of kinetic rate constants,
kd/ka. A lower value of KD represents greater affinity of the ligand-analyte interaction.
For kinetic applications, the ligand immobilized has to be low to avoid mass transport
effects. For best kinetic results, the maximum analyte binding capacity, Rmax is in the range
50-150RU. The level of ligand to be immobilized is calculated using the manufacture’s
recommended formula, Rmax = (MWa/MWL) * RL * Sm. The concentration range of analyte
is 0.1KD to 10KD.

4.6 Regeneration Scouting

The analyte has to be completely dissociated from the ligand to start a new analysis
cycle. The extent of dissociation in running buffer varies with the type of analyte and how
strong it binds to the ligand. A regeneration solution has to be passed over the surface to
remove the bound analyte from the ligand of the surface. The conditions for regeneration
have to be such that the ligand over the surface is not damaged or does not lose activity.
Regeneration scouting method helps in finding suitable regeneration conditions for the
ligand, which is determined for our system as described in Chapter 5 below.
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CHAPTER 5 Materials and Methods

5.1 Materials

SPR measurements are performed using Biacore 3000 system. The antibodies, buffers
and reagents used for the experiments are listed below.

5.1.1 Antibodies

The receptor sEGFR was used as the ligand and the growth factor EGF and the cancer
drug Cetuximab were used as analytes to study the interaction. Also the binding interaction
of sEGFR with a peptide (P-13), designed specifically for this target was also studied. The
human recombinant sEGFR was purchased from Research Diagonostic Inc and EGF was
purchased from Sigma. Another 100mg/ml of EGF was purchased from BD Biosciences
for additional experiments. The Cetuximab was purchased from the pharmacy of Massey
Cancer Center. The P-13 was synthesized using CEM® Automated Microwave Peptide
Synthesizer.

5.1.2 Buffers and Stock Solutions
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The buffers and other reagents used for Biacore experiments are listed in the Table
5.1-1 below. All solutions were made up of DI H2O from Millipore.

Table 5.1-1 Buffers and Stock solutions for Biacore

Name of the Solutions
HBS-EP
Amine Coupling Solutions
Regenerations Solutions
Ligand stock solution
BIAnormalizing solution
BIAdesorb solution 1
BIAdesorb solution 2
BIAdisinfectant solution

Components
Aqueous buffer containing 0.01 M HEPES pH 7.4, 0.15
M NaCl, with 3mM EDTA and 0.005% Surfactant P20.
EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride); and NHS (N-hydroxysuccinimide); and
Ethanolamine 1M.
Glycine 2.0; or Glycine 2.5; or NaOH 10mM; or NaOH
50mM;
10mM NaAc pH 5.2±0.1
70% glycerol
0.5% sodium dodecyl sulphate (SDS)
50mM glycine-NaOH pH 9.5
Sodium hypochlorote with 8-12% active chlorine

5.1.3 Reagents and Stock Solutions for Peptide Synthesis

The reagents and other solutions used for peptide synthesis and purification are listed
in the Tables 5.1-2, 5.1-3, 5.1-4 below. All amino acid solutions are prepared in DFM.

Table 5.1-2 Reagents and Stock Solutions for peptide synthesis.

Name of the Solutions
Main Wash
Activator
Activator Base
Deprotect

Components
DFM (N, N-Dimethylformamide); and DCM
(Dichloromethane).
8.53g HBTU dissolved in 45ml DMF.
A
solution
of
17.4ml
DIEA
(N,
NDiisopropylethylamine) mixed with 32.6ml of NMP (1Methyl-2-Pyrrolidone).
A solution of 100ml piperidine, 400ml DFM (N, N40

Capping mix
Cleaving mix
Peptide precipitate mix

Dimethylformamide) and 6.75g HoBt.
20% of Acetic anhydride in DMF (4ml of Acetic
anhydride in 16ml DMF).
A solution of 250µl DODT (3, 6-Dioxa-1, 8-octanedithiol), 250µl TIS (Triisopropylsilane), 250µl H2O
mixed in 9.25µl of TFA (Trifluoroacetic acid).
Diethyl ether (or cold ether).

Table 5.1-3 Reagents and buffers used for protein purification (HPLC).

Name of the Solutions
B.conc
A. conc

Components
0.1% TFA in MeCN (Acetonitrile).
0.1% TFA in DI H2O.

Table 5.1-4 Solutions used for MALDI Mass Spec.

Name of the Solutions
Matrix

Components
500µl of 0.1% TFA mixed in the solution of 10mg
crystallized CHCA and 500ul Acetonitrile.

5.2 Equipment

5.2.1 Biacore 3000

The binding studies of the proteins and antibodies were carried out using Biacore
3000 instrument from GE Healthcare. The experiments were carried out at 25ºC with a
data collection rate of 1Hz. The running methods were created using the Biacore 3000
control software 3.0. The Sensograms were evaluated using BIAevaluation 3.0 software
provided by the manufacturer. Maintenance of the instrument was performed according to
the supplier’s instructions.
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5.2.2 CEM Microwave Peptide Synthesizer

Liberty-Automated microwave peptide synthesizer from CEM Corporation was used
to make the peptide P-13. This instrument uses microwave energy to drive biochemical
reactions resulting in higher purity peptides made 10 times faster than by conventional
methods. All amino acid bottles and reagent bottles were cleaned and back flushed before
starting the synthesis.

5.2.3 Other Instruments

MALDI Mass Spectrometer was used to check the mass of the peptide synthesized.
The data was collected and analyzed using the Mass Lynx software provided by the
manufacturer. HPLC (High Performance Liquid Chromatography) was used to purify the
peptide. The software used for analysis of data was LC solutions provided by the
manufacturer. The Eppendorf Microcentrifuge was used to filter the peptide samples for
HPLC purification. The samples were filled in microcentrifuge vials and were centrifuged
at 13.5rpm speed for 1min. Rotary Evaporator from Fisher Scientific was used to remove
solvents from the peptide solution after purification.

5.3 Peptide Synthesis
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The peptide synthesis was carried out using Automated Microwave Peptide
Synthesizer from CEM Corporation. All amino acids and reagents needed for synthesis
were freshly prepared before the start of the experiment.

5.3.1 Synthesis of P-13

The amino acid sequence was input to the instrument software which subsequently
calculates the amounts of reagents required for the synthesis. The amino acids were
prepared dissolving the calculated amounts of respective samples in the given volumes of
DMF as recommended by the CEM program. The activator used was HBTU dissolved in
DMF and the activator base was a solution of DIEA and NMP. A solution of piperidine,
DMF and HOBt was used as deprotect mix and 20% Acetic acid in DMF was used as a
capping mix for the synthesis. The resin used was Fmoc-PAL-PEG. The synthesis ran for
9hrs for this 13-residue peptide.

5.3.2 Washing and Cleaving the Peptide

The resin having the peptide was washed with DCM after filtering it out from DFM.
The excess DCM was filtered out and the resin with peptide was subject to cleavage in a
solution of DODT, TSI, H2O and TFA. The resinous solution was filtered and the filtrate
was mixed with cold ether which was centrifuged to give out a precipitate and stored at 20°C as peptide.
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5.3.3 Purification of the peptide

High Performance Liquid Chromatography (HPLC) was used to purify the peptide
from other salts after cleaving it from the resin. A peptide solution of 20mg/ml
concentration was made by dissolving a pinch of the peptide in 0.1%TFA & H2O. An
analytical procedure was carried out on HPLC to determine the gradient of mobile phase
component “B” for peptide extraction. After obtaining the gradient, the separation was
carried out on a large scale and the purified solution was tested on Mass Spec to reconfirm
the presence of the peptide by checking the mass of the obtained sample. The mass
acquisition range specified was from 800-3000Dalton. A rotary evaporator was used to
remove solvents by evaporation from the peptide solution. The obtained peptide is weighed
using a mass balance and stored at -20°C for Biacore applications.

5.3.4 Concentration of the peptide

Biophotometer was used to determine the concentration of the peptide at A280nm, since
using a mass balance has not proven to be an accurate way to get the weight of the peptide;
the peptide mass synthesized (~mg) is too small and even a minute quantity of water or
other substances sticking to the vial would affect the accuracy of weight shown. The
peptide was dissolved in 1ml DI H2O and 3µl of H2O was used as reference blank. Peptide
volume of 3µl was given as sample and the absorbance value was displayed on the screen.
The concentration of the peptide is then calculated using the equation A=ebc (Beer44

Lambert law), where, A is the absorbance of the sample, b is the path length, c is the
concentration in mol/l and e is the extinction coefficient of the peptide which is calculated
as referenced in Kibbe WA et al., 2007. Multiplying the calculated concentration with the
molecular weight of the peptide (1688g/mol) gives the concentration of the peptide in g/l
which can be converted to mg/ml.

5.4 Surface Preparation

A research grade CM5 sensor chip from Biacore was used to immobilize ligand on
flow cell 2 or 4 using flow cell 1 or 3 as reference accordingly. The bare chip was
conditioned by passing 50mM NaOH for five cycles for 1min through all the flow cells.
This procedure removes all loosely bound dextran material from the surface. Then the chip
was normalized according to the supplier’s instructions. This gives maximum sensitivity of
the chip. The sensor surface and sample blocks were maintained at 25°C.

5.4.1 Preparation of sEGFR as ligand

The human recombinant soluble EGFR (purchased from Research Diagnostic Inc)
was used as the ligand. The ligand was diluted with 10mM sodium acetate buffer to a
concentration of 25µg/ml. The ligand was diluted to give a solution of pH 5.2±0.1 which
falls in the required range (3.5 and isoelectric point of the ligand). The carboxymethylated
dextran on the sensor chip is negatively charged above the pH 3.5 and electrostatic
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attraction provides an efficient means for concentrating positively charged ligands on the
surface. Hence, the ligand was prepared in 10mM NaAc (pH 5.2±0.1) to give a final
concentration of 25µg/ml (Iyer et al., 2007). This concentration was used for the binding
studies of all the three analytes- EGF, Cetuximab and peptide P-13.

5.4.2 Immobilizing sEGFR on CM5

The amine coupling kit from Biacore was used for the procedure. The EDC and NHS
solutions were prepared according to the manufacturer’s instructions. The ligand level to
be immobilized was determined using the formula as discussed in Chapter 4,
Rmax = (analyte MW/ligand MW) * Stoichiometry * RL.
The binding capacity of the surface depends on the ligand immobilization level. Here
RL is the immobilization level of the ligand which determines the maximum response,
Rmax. For the experiment, the Rmax has been considered to be in the range 50-150RU. Here,
the molecular weight of sEGFR is 82kD. The molecular weights of EGF, Cetuximab and
the peptide P-13 are 6kD, 152kD and 1.688kD respectively. Fitting in the values of
molecular weights for the given proteins in the equation, a suitable range for the
immobilization level of sEGFR was determined for all three analytes. Considering only
60% of the ligand is active on the surface, the immobilization level is scaled up
accordingly. Hence an immobilization levels in the range 2500-5500RU for EGF, about
100-400RU for Cetuximab and about 2500-4000RU for P-13 were achieved.
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The sensor chip has four flow cells out of which flow cells 1 or 3 were used as
reference cells and immobilization was done on flow cells 2 or 4. Immobilization was
carried out in two ways: Using ‘Aim for Immobilized level’ wizard or using ‘Specify flow
rate and injection time’ wizard. The first few experiments were carried out using ‘Aim for
immobilized level’ wizard with target RU set to 2500RU for EGF-sEGFR interaction. The
later were carried out specifying flow rate and injection time. The flow rate and injection
time was specified for all Cetuximab-sEGFR and P-13-sEGFR experiments. The flow rate
and injection time were adjusted such that the target RU (as per calculations above) was
reached.

5.5 Kinetic Analysis of protein-protein or peptide-protein interactions

The kinetic studies of sEGFR-EGF, sEGFR-Cetuximab and sEGFR-P-13 were carried
out using the kinetic analysis wizard. HBS-EP was used as the running buffer.

5.5.1 EGF Interaction

EGF was serially diluted in sterile HBS-EP buffer with the dilution factor of 2
between each concentration. The concentration range used was 1000nM to 10nM and a
zero concentration sample was included for reference subtraction. The analyte
concentrations were adjusted such that the lowest concentration barely shows binding to
the ligand and highest concentration reaches saturation. The wizard template had the run
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order sorted from low analyte concentration to high analyte concentration. The samples
were injected over the surface at a flow rate of 30µl/min with a 3min association pulse and
15min of dissociation, without the need for a regeneration step (Iyer et al., 2007).

5.5.2 Cetuximab Interaction

The drug Cetuximab, also called C225 was diluted in sterile HBS-EP buffer to a
series of concentrations. The analyte concentrations for analysis ranged from 0.2nM to
30nM with a dilution factor of 2 between each concentration. Also, a high concentration
sample of 100nM and a zero concentration (plain buffer) sample were included for
analysis. The samples were run from low to high order at a flow rate of 30µl/min with
2min association and 10min dissociation. In order to find the optimal conditions for
dissociation of the ligand-analyte complex, a regeneration scouting method was run with
glycine as regeneration solution at three different pH values. The solutions were tested
from mild to harsh conditions. The solutions used were glycine pH 3.0, glycine pH 2.5,
glycine pH 2.0. It was observed that the regeneration was best when glycine pH 2.5 was
used as regeneration solution. In this case, the ligand surface returned to within 1% of its
initial RU value. Hence, the surface was regenerated with a single injection of 10mM
glycine (PH 2.0) for 1 min after dissociation and a stabilization time of 1min was included.

5.5.3 Peptide Interaction
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The peptide P-13 was initially diluted using HBS-EP buffer to higher concentrations
and tested on the sensor chip immobilized with sEGFR for binding. The concentrations
were increased in the next subsequent runs when significant binding was not observed. The
regenerations conditions were determined by performing regeneration scouting with
regenerations solutions glycine at pH 3.0, pH 2.5, pH 2.0, pH 1.5 and 10mM NaOH. The
solutions were tested from mild to harsh conditions. After determining the concentration of
analyte which gives good binding to the chip and a suitable regenerations solution which
dissociates the complex, analyte dilutions were carried out with a minimum concentration
of 200uM and maximum concentration of 1000µM. A zero concentration sample was
included for reference subtraction. Kinetic analysis wizard was run with the series of
concentrations with an association time of 5mins and dissociation time of 15mins at flow
rates 30µl/min. The surface was regenerated with a single injection of 10mM NaOH for
30seconds after dissociation and a stabilization time of 1min was included.
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CHAPTER 6 Results and Discussion

The results of binding kinetics studies of antibodies EGF, Cetuximab and P-13 with
sEGFR carried on Biacore are presented in this chapter along with mass and purification
data of the peptide P-13. Comparisons to previously reported results are given for the EGFsEGFR system and Cetuximab-sEGFR system. We demonstrate that our Biacore results
for the EGF-sEGFR system are consistent with cell culture results.

6.1 Synthesis of P-13

6.1.1 Calculating the mass of P-13

The mass of the peptide was calculated using peptide mass calculator v3.2 (Jef
Rozenski (1999)) available on web by inputting the peptide sequence. The peptide mass
was calculated considering that the N-terminal of the peptide was acylated and C-terminal
was an amide bond. The calculated peptide mass was 1688.737 Dalton.

6.1.2 Determining P-13 mass using MALDI Mass Spec

50

MALDI Mass Spectrometer was used in molecular weight confirmation of the peptide
P-13. The peptide was tested on MALDI before and after purification. Samples to be
analyzed were prepared at ratio 2:8 peptide digest to matrix (crystallized α-Cyano-4hydroxy-cinnamic acid, CHCA), and subsequently dried on a stainless steel MALDI plate.
The mass data of the P-13 before purification (data not shown) and mass data after
purification of P-13 using HPLC was consistent and confirms the presence of the peptide
P-13. The mass data after purification is shown in Figure 6.1-1.

Figure 6.1-1 Data from Mass Spec for purified P-13.

The purified peptide from HPLC was collected in a vial and the solvents were
evaporated using a rotary evaporator. The weight of the empty vial was recorded and the
weight of the vial after rotary evaporation was recorded. The weight of the actual peptide
was determined by carrying subtraction between the two weights obtained. One ml of DI
H2O was added to the known weight of the peptide formed and Mass Spec was run on the
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sample. Also, the sample was tested for concentration on Biophotometer since mass
balance can show drastic variations from the actual weight even with a minute quantity of
other solvent present in the sample. The data of the Mass Spec is shown in the Figure 6.12. This confirms the presence of the peptide after rotary evaporation.

Figure 6.1-2 Data from Mass Spec for purified P-13 after solvent evaporation.

6.1.3 Purification of P-13

The peptide purification was carried on HPLC as described in Chapter 5. The peptide
was recovered by gradient elution using a linear 50min gradient at a flow rate of
0.44ml/min. Detection was by absorbance at 280nm. Fractions were collected and analyzed
using Mass Spectrometer for peptide mass. The fraction between 8-8.5min was identified
to contain the peptide. The purification was then carried out on a large scale at a flow rate
52

of 10ml/min and the peptide was collected between 18-19mins. The peptide peak on HPLC
is shown in Figure 6.1-3.

Figure 6.1-3 Chromatogram obtained from purification of P-13 using HPLC. The fragment was eluted
between 18.5-19.6min, detected at wavelength 280nm.

6.2 Immobilization of sEGFR on CM5 sensor chip

The immobilization of sEGFR on CM5 sensor chip was done using amine coupling as
described in the previous chapter. The immobilization levels (in RU) varied with analyte
used for analysis.
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Figure 6.2-1 Immobilization of sEGFR using amine coupling. Surface is activated with EDC/NHS mixture
before the ligand is injected to the surface and ethanolamine is used to deactivate the surface after ligand
binding.

The sEGFR immobilization for EGF interaction studies was between 3000-5500RU.
Cetuximab interaction studies were carried out with sEGFR immobilization level between
100-400RU. The immobilization level for peptide P-13 studies was between 25004000RU, each calculated according to the Rmax equation as described in Chapter 4. A
representative sEGFR amine coupling Sensogram is shown in Figure 6.2-1.

6.3 Kinetic analysis

The data obtained from binding studies of sEGFR with antibodies EGF, Cetuximab
and P-13 are presented here.
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6.3.1 Binding studies with EGF

The sEGFR ligand was immobilized on flow cell 2 using flow cell 1 as reference. For
kinetic analysis, varying concentrations of EGF were passed over the sensor surface in
order of increasing slope from the lowest concentration to the highest concentration. The
running buffer was HBS-EP and the injected concentrations of EGF were 1000 (the curve
with the highest RU), 500, 250, 125, 60, 30, 15 and 10nM. Data were analysed at the
above mentioned concentrations of EGF with several densities of sEGFR (3357, 3700,
5500RU) immobilized on the surface. The representative Sensograms of the evaluated data
are presented in Figure 6.3-1 below.
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Figure 6.3-1a Kinetic analysis of EGF with sEGFR: Data fitted using 1:1 Langmuir binding model. Various
concentrations of EGF were injected at 30µl/min over 3357RU immobilized sEGFR and reference surface
(activated and deactivated by EDC/NHS and ethanolamine). Curves shown are reference subtracted.
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Figure 6.3-1b

Kinetic analysis of EGF with sEGFR: Data fitted using heterogeneous ligand parallel

interactions model. The data used is same as in Figure 6.3-1a.

The curves exhibit fast on and off rates and reach equilibrium binding rapidly. Both
rate and equilibrium binding constants were determined fitting data using simultaneous
ka/kd model (data fitted globally) as well as carrying over analysis of equilibrium binding
data in Scatchard format.
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Figure 6.3-2 Scatchard plot of EGF binding to sEGFR. Steady state binding data was obtained by plotting
Req against concentration (shown in the right upper corner). Req/Conc was calculated and plotted against
concentration for Scatchard plot.

The Scatchard plot of equilibrium binding data of EGF with the receptor sEGFR is
shown in Figure 6.3-2. The data seem to show deviations from linearity which indicates
that there are more than one independent binding events occurring.
The x-intercept in the Scatchard plot of Biacore data represents the maximum analyte
binding capacity Rmax (~65 RU). For the immobilization of 3357RU, the theoretical Rmax
came up to be 251 RU assuming 1:1 interaction of EGF with sEGFR. This suggests that
only 25% of the biosensor surface was either active or had immobilized ligands in
accessible orientations.
For all sEGFR surface densities, the data from the primary analysis showed a poor fit
(R>0.2) to 1:1 Langmuir interaction model suggesting that more complex binding
mechanisms were operative. The curve fitting to the heterogeneous ligand- parallel
intereactions model was significantly better indicating two independent binding sites in the
system. For 3357RU of sEGFR immobilization, one of the two binding sites was a low
affinity binding site which contributed to 90% of the total binding with an apparent ka of
3.75e5M-1s-1 and kd of 0.0406s-1, resulting in a calculated KD of 108nM which is in good
agreement with the literature KD for EGF and sEGFR interaction, as shown in Table 6.3-1.
The high affinity binding site is just 10% of the total binding and has a calculated KD of
about 5.4nM. For 5500RU sEGFR surface density, the kinetic rate constants agreed
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approximately to that of the previously obtained values except that the high affinity
binding increased to 16% of the total binding.
Mass transfer limitations were tested with higher concentration of EGF (100nM) at
flow rates 5µl/min, 15µl/min and 75µl/min. Figure 6.3-2 shows a representative
Sensogram of EGF kinetics at three different flow rates. The kinetics of the binding of
EGF to sEGFR changed less than a few percent with changes in flow rate, indicating that
the reaction is not mass transfer limited.
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Figure 6.3-3 Data from Mass transfer control experiment. Kinetics of 100nM EGF at different flow rates
(5µl/min, 15µl/min, and 75µl/min) was determined. Kinetics of EGF binding was same at all flow rates.

The equilibrium binding constants are reported in the Table 6.3-1 for EGF and
sEGFR interaction. Comparisons are also given with that of literature values.
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Table 6.3-1 Summary table for equilibrium binding constants for EGF/sEGFR interaction.

Ligand Analyte Low Affinity Binding High Affinity Binding
KD (nM)
kd (s-1)
KD (nM)
kd (s-1)
Studies sEGFR
EGF
115±10
0.04
13±8
0.002

Our
(Biacore)
Iyer et al., 2007 sEGFR
(Biacore)
Shiqing Li et al.,
EGF
2005 (Biacore)
Wade et al., 2002 mEGF
(Biacore)
Domagala et al., rhEGF
2000
J Schlessinger et EGFR
al., 1986 (In cells)

EGF

110

-

-

-

sEGFR

130±3

-

-

-

sEGFR

400

0.042

28

0.02

sEGFR

439

0.066

60

0.013

EGF

1-10

-

0.01-0.1

-

6.3.2 Binding studies with Cetuximab

Cetuximab was used in increasing concentrations run from low order to high using
kinetic analysis. HBS-EP buffer was used to make serial dilutions and the concentrations
injected were 50, 20, 5, 2, 1, 0.2, 0.02nM. A 0nM sample was also injected for reference
subtraction. The interaction was tested for mass transfer limitations using 0.2nM and 20nM
concentrations at flow rates 5µl/min, 15µl/min and 75µl/min and the data obtained did not
seem to be affected with change in flow rates indicating the reaction is not mass transport
limited (data not shown). The data was analysed with varying concentrations of Cetuximab
and two different surface densities of sEGFR (100 and 300RU). The representative
Sensograms of evaluated data are presented in Figure 6.3-4.
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Figure 6.3-4

Kinetic analysis of C225 with sEGFR: various concentrations of C225 were injected at

30µl/min over 100 RU immobilized sEGFR and reference surface (activated and deactivated by EDC/NHS
and ethanolamine). Curves shown are reference subtracted.

The Sensograms fitted using 1:1 Langmuir binding model showed significant
deviations for higher surface density (data not shown). As the surface density was
decreased to 100RU, 1:1 Langmuir binding model (data not shown) showed a better fit
except that the higher and lower concentrations for analyte still showed deviations.
However, the curve fitting was good using Bivalent analyte model (where the analyte can
bind to two ligands simultaneously on the surface) for all surface densities. The curves
showed a slow dissociation with apparent ka of 8.36e5M-1s-1 and kd of 1.81e-3s-1, resulting
in a calculated KD of 0.2nM which is in good agreement with the literature.
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The equilibrium binding constants for Cetuximab and sEGFR interactions are
reported in the Table 6.3-2. Comparisons are also given with literature values.
Table 6.3-2 Summary table for equilibrium binding constants for Cetuximab/sEGFR interaction.

KD (nM)
0.15±0.05
2.3±0.5
0.2

Our studies (Biacore)
Shiqing Li et.al, 2005 (Biacore)
Neil I. Goldstein et al., 1995 (Biacore)

kd (s-1)
0.002
-

6.3.3 Binding studies with P-13

P-13 was used in increasing concentrations run from low to high order using kinetic
analysis wizard. HBS-EP buffer was used to serial dilutions and peptide concentrations of
1000, 800, 600, 400, 500, 300 and 200µM were injected to determine steady state binding
affinity. The interactions were tested for mass transfer limitations using 400µM
concentration at flow rates 5, 15 and 75µl/min and it did not seem to be affected by mass
transport.
The Sensograms showed fast dissociation and the curves did not start to plateau to
determine steady state binding affinity. The highest concentration (1000µM) seemed to
show nonspecific binding and therefore was eliminated from analysis. The data was first
fitted for dissociation and a kd of 0.08±0.01s-1 was calculated. Considering the dissociation
rate constant to be 0.08s-1, data was fitted for an association constant ka of 150M-1s-1 and a
corresponding KD of 500µM was observed for most curves. The fitted data for association
as well as dissociation is shown in the Figure 6.3-5.
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Figure 6.3-5 Kinetic analysis of P-13 with sEGFR. Data was fitted using various concentrations of P-13
(800, 600, 400, 300 and 200µM) injected at 30µl/min over sEGFR immobilized on the sensor surface.
Kinetic rate constants were determined by fitting the data for dissociation (A) and association separately.
Equilibrium dissociation constant was calculated from the obtained rate constants.

6.4 Discussion
We have determined that the dissociation rate constant for EGF binding to sEGFR is
0.04s-1 which is comparable to the rate constants shown in previous cell culture studies.
Table 6.3-1 shows the equilibrium dissociation constant for EGF and sEGFR binding
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assuming heterogeneous ligand parallel interactions model and is comparable with Iyer et
al,. The affinity of sEGFR measured by Biacore is 100 fold lower than that in cells. This
may be due to the fact that extra cellular domain of EGFR has much lower binding affinity
than that of EGFR full length (Brown et al., 1994). Also, deglycosylation of the
recombinant protein used might have further decreased the affinity suggesting that the KD
values obtained using SPR studies may be 100 fold higher than measured in vitro.
There have been conflicting results on the binding stoichiometry of the EGF/EGFR
interaction (Domagala et al., 1999). The binding stoichiometry using full length EGFR
purified by affinity chromatography from A431 cells is reported to be 1:1; by Weber et al.,
1984 in their studies. The later studies in cells, demonstrated that EGF binds to EGFR with
two distinct dissociation constants: a minority (2%–5%) of high-affinity (KD~0.1nM)
receptors and a majority (95%–98%) of low-affinity (KD~10nM) receptors (Schlessinger et
al., 1986, 88). In Biacore studies carried over by Domagala et al., they reported that global
analysis of EGF/sEGFR binding curves indicated that a simple 1:1 interaction did not
adequately describe the experimental data, and that more complex interactions were
operative. Additionally, competition analysis of the data obtained using either direct
measurement of free sEGFR using Biacore or Fluorescence Anisotropy experiments
yielded biphasic Scatchard plots indicative of multiple binding sites, with 10-15% of the
high affinity sites (Domagala et al., 2000).
In our studies, we immobilized sEGFR in order to closely imitate the natural system.
The flexibility of the dextran matrix and high local concentrations of immobilized
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receptors made it possible to form complexes that mimic the cell surface better than
solution phase assays (Myszka et al., 1999). Nonetheless, the data fitting using
simultaneous ka/kd model indicated a two state binding of EGF and sEGFR with a 90% low
affinity site with KD of 115±10nM which is consistent with KD of EGF binding to sEGFR
established in Li et al., and Iyer et al. The other 10% is high affinity binding and the
physical reasons causing this are unclear.
Since Cetuximab is a bivalent monoclonal antibody, data fitting for C225 interaction
with sEGFR was done using bivalent analyte model. The dissociation constant was shown
in Table 6.3-2 in comparison with literature. We immobilized sEGFR on the surface and
made C225 to flow on the ligand. When the surface density of sEGFR was 100RU, the
data fitted well to 1:1 Langmuir model. As surface density of sEGFR was increased, fitting
showed significant deviations. This may be due to the increased avidity effects on the
surface. Avidity could be described as follows. If an antibody is in solution, it has the
potential to cross-link with two antigens on the surface. This will result in an apparent
higher affinity and the kinetics cannot be described with a simple interaction model
(Myszka et al., 1999). Studies by Shiqing Li et al., showed that Cetuximab binds to
sEGFR with a dissociation constant of 2.3nM which is 10 fold greater than what we got in
our studies. This may be due to the difference in experimental methods adopted and the
nature of the Cetuximab used. Li et al., used a monovalent Fab fragment in their study
where as we used bivalent antibody. Also, in our studies, we reported the dissociation rate
constant for immobilized sEGFR with Cetuximab, as an analyte, regeneration was possible
in our system. This was practically not possible with sEGFR binding to immobilized Fab
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as the sEGFR sticks very tightly to the Fab and never comes off under normal buffer
conditions (Li et al., 2005).
P-13 interactions with sEGFR showed a binding with significantly lower affinity as
compared to the prototypical ligands such as EGF. The KD of the peptide is reported to be
500µM and the kinetic dissociation rate constant is 0.08±0.01s-1. Although the equilibrium
dissociation constant is way too high for comparison, the dissociation rate constant seems
to be comparable to a nano molar binder, Hydroxybenzylpindolol (Rimon et al., 1980). As
the association rate constant is very low, the peptide is rendered as a very weak binder.
This suggests that the binding region of the peptide on the receptor could be highly
inaccessible. We may conclude from this study that target location plays an important role
for peptide therapeutics. In our study, to get a more promising binder, the upper regions of
domain III must be considered as target.
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CHAPTER 7 Future Work

•

In order to obtain more reliable kinetic rate constants and equilibrium binding
constant for the P-13-sEGFR interaction, it is necessary to repeat the Biacore
experiments more number of times with higher concentrations of peptide. Due to
the limited availability of resources, we had to optimize our experiments.

•

To obtain a wider knowledge on interaction of the peptide P-13 with the receptor
and to determine if the peptide has any inhibiting effect on EGFR cell signaling, it
is recommended to carry on cell studies with the peptide.

•

In order to explore the structure of high affinity binding of EGF and sEGFR, it is
suggested to recover the EGF-sEGFR complex and carry forward x-ray
crystallography studies on the complex.
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